Loading viewer...
investor_presentation
Format: PDF investor_presentation
See Last Page for Key Disclaimers & Disclosures The Abstract Portfolio at Marketplace by Seeking Alpha EARNINGS REPORT – Q4 FY2021 22nd February 2022 Compan y Post - Earnings Rating Palantir Technologies Bullish Ticker: PLTR (NYSE) Relative Risk: Neutral Sector | Industry: Techno
See Last Page for Key Disclaimers & Disclosures
The Abstract Portfolio
at Marketplace by Seeking Alpha EARNINGS REPORT – Q4 FY2021
Compan y Post - Earnings Rating
Palantir Technologies Bullish
Ticker: PLTR (NYSE) Relative Risk: Neutral
Sector | Industry: Technology | Software Portfolio Pick? Yes - Core
Trends: Software Transformation , Artificial Intelligence Earnings Reaction : Neutral
Sourc e: Charts and Raw Data from Koyfin
Palantir released its Q4 Earnings , recording a good sales beat, and rather on-
trend financials considering consensus. A 34% YoY sales growth for Q4 might be
nothing to boast about in the scheme of high -flying SaaS, but the drivers under
the surface are changing dramatically.
Government business appears to be flatlining on sales growth towards 0% YoY.
However, the Commercial Business is accelerating f ast at an exponential rate .
Palantir added +200% YoY on the Commercial customer count. Given the Land -
Expand -Scale business model that leads to exponential revenues from customers
over time, this vertical should more than compensate for the weakness in the
FY22 will likely have sales acceleration, not deceleration, like we’ve seen this
past year. It makes complete sense to position our stock for these exponential
mechanisms that will manifest in the fundamentals 1 -year out.
At a NTM EV/S of 9.9x, PLTR is trading at a bargain price . Macro -concerns might
point to perhaps lower customer expansion, but the trends are showing
immense strength . The market has over -reacted on the negative end in my view.
Earnings Release here.
Earnings Presentation here .
Key Metrics & Valuation Multiples
Share Price $10.41
1-yr Total Return -64.2%
Low | High 52 Week $10.3 | $30.19
Preview truncated — download the full document for the complete content.
investor_presentation
47 Pages
Cree LED
Gujarat Themis Biosyn (GTBL) Investor Presentation 2021
investor_presentationinvestor_presentation
27 Pages
Gujarat Themis Biosyn Limited
MabVax Therapeutics MBVX 2017 Corporate Presentation
investor_presentationinvestor_presentation
46 Pages
MabVax Therapeutics Holdings